|Chemotherapy Agents||Incidence (%)||Frequency of Use|
|Capecitabine (Xeloda) (71,74,83–85)||3–9||+++|
|Fluorouracil (Adrucil) (8,70,71,73–79)||1–68⁎||+++|
|Paclitaxel (Taxol) (90,91)||<1–5||+++|
|Docetaxel (Taxotere) (10,92)||1.7||++|
|Monoclonal antibody-based tyrosine kinase inhibitor|
|Bevacizumab (Avastin) (10,93,94)||0.6–1.5||++|
|Small molecule tyrosine kinase inhibitors|
|Erlotinib (Tarceva) (10)||2.3||+++|
|Sorafenib (Nexavar) (10,96)||2.7–3||+++|
For an explanation of the + symbols, please see Table 1.
↵⁎ The incidence of ischemia varies widely in the literature for 5-fluorouracil due to the differences in study design, definition of ischemia, and numbers of patients. Medication manufacturers and locations: Xeloda, Roche Laboratories Inc., Nutley, New Jersey; Adrucil, Sicor Pharmaceuticals, Irvine, California; Taxol, Bristol-Myers Squibb, Princeton, New Jersey; Tarceva, OSI Pharmaceuticals Inc., Melville, New York; Nexavar, Bayer HealthCare Pharmaceuticals, Inc., Wayne, New Jersey; see Table 1for others.